Scarica l'app Stockscreener
0.3223
4.30%
0.0133
Dopo l'orario di chiusura:
.31
-0.0123
-3.82%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNS Giù?
Forum
Previsione
Frazionamento azionario
Marinus Pharmaceuticals Inc Borsa (MRNS) Ultime notizie
Layoff Tracker: J&J, Merck Trimming Workforces in China - BioSpace
Marinus Pharmaceuticals Reports Q3 2024 Financial Results and Strategic Developments - MSN
MRNS (Marinus Pharmaceuticals) Degree of Operating Leverage : 65.26 (As of Jun. 2024) - GuruFocus.com
Marinus Pharmaceuticals Third Quarter 2024 Earnings: Revenues Disappoint - Simply Wall St
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results - Yahoo Finance
Marinus Pharmaceuticals Lays Off 45% of Employees - BioSpace
Marinus Pharmaceuticals Faces Financial Turmoil Amidst Class Action Lawsuit - TipRanks
Marinus Pharmaceuticals Reports Q3 Growth in ZTALMY Revenue - TipRanks
Marinus Pharmaceuticals' SWOT analysis: navigating challenges in rare epilepsy stock - Investing.com India
Marinus Pharmaceuticals: Q3 Earnings Snapshot - Darien Times
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates - MSN
Marinus Pharmaceuticals Inc Reports Q3 2024 Revenue of $8.54M, G - GuruFocus.com
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
Marinus Pharmaceuticals Faces Setback with Phase 3 TrustTSC Trial - MSN
Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment - Investing.com Canada
Greenlane Holdings to Distribute CURB’s Innovative Inhalation Device: A Game-Changer? - BP Journal
Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment By Investing.com - Investing.com South Africa
Marinus downgraded after setback to late-stage trial - MSN
Marinus Pharmaceuticals Hosts Investor and Analyst Day - MSN
TD Cowen Downgrades Marinus Pharmaceuticals (MRNS) - MSN
Marinus tanks after late stage trial for treatment of seizures in TSC fails to meet main goal - MSN
Marinus Pharmaceuticals (MRNS) Halts Ganaxolone Development for TSC After Phase 3 Trial Failure - BP Journal
Marinus Pharmaceuticals Expands Intellectual Property Portfolio with New ZTALMY® Patent - MSN
Marinus Pharmaceuticals price target lowered to $1 from $3 at RBC Capital - TipRanks
Marinus stock downgraded after trial setback (MRNS:NASDAQ) - Seeking Alpha
HC Wainwright Reiterates "Neutral" Rating for Marinus Pharmaceuticals (NASDAQ:MRNS) - MarketBeat
Marinus’ clinical trial of ganaxolone fails to meet primary endpoint - Yahoo! Voices
Marinus Pharma Halts Development After Seizure Drug Fails Trial - Medical Dialogues
JMP Securities Downgrades Marinus Pharmaceuticals (MRNS) - MSN
Marinus halts ganaxolone development after trial setback - Investing.com India
Jefferies cuts Marinus Pharma to hold, slashes target to $0.50 - Investing.com India
Marinus Pharmaceuticals downgraded to Hold from Buy at Jefferies - TipRanks
Jefferies cuts Marinus Pharma to hold, slashes target to $0.50 By Investing.com - Investing.com UK
Marinus halts ganaxolone development after trial setback By Investing.com - Investing.com Australia
Truist cuts Marinus Pharma to hold, drops price target - Investing.com
Truist cuts Marinus Pharma to hold, drops price target By Investing.com - Investing.com UK
Baird cuts Marinus Pharma target to $0.50 on failed study - Investing.com
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options - AOL
Marinus Pharmaceuticals price target lowered to 50c from $2 at Baird - TipRanks
Marinus Pharmaceuticals downgraded to Market Perform at JMP Securities - TipRanks
Marinus to trim workforce, weigh 'strategic alternatives' after another Ztalmy trial miss sends shares tumbling - FiercePharma
Marinus Pharma stock plunges to 52-week low of $0.52 - Investing.com
Marinus hits record low after discontinuing development of rare disease drug - XM
Marinus Pharma stock plunges to 52-week low of $0.52 By Investing.com - Investing.com Canada
Marinus Pharmaceutical Shares Plumb New Depths After Study Failure - MarketWatch
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):